Catheter Directed Thrombolysis for Deep Vein Thrombosis during the First Trimester of Pregnancy: Two Case Reports

2008 ◽  
Vol 58 (2) ◽  
pp. 127
Author(s):  
Kum Rae Kim ◽  
Won Kyu Park ◽  
Jae Woon Kim ◽  
Woo Hyung Kwun ◽  
Bo Yang Suh ◽  
...  
1998 ◽  
Vol 79 (03) ◽  
pp. 517-519 ◽  
Author(s):  
Stephane Heymans ◽  
Raymond Verhaeghe ◽  
Luc Stockx ◽  
Désiré Collen

SummaryThe feasibility of catheter-directed thrombolysis with recombinant staphylokinase was evaluated in six selected patients with deep vein thrombosis. The patients underwent intrathrombus infusion of recombinant staphylokinase (2 mg bolus followed by a continuous infusion of 1 mg/h). Heparin was given via the catheter as a bolus (5000 U) and as a continuous infusion (1000 U/h). Complete lyis was obtained in five patients and partial lysis in one patient. Complications consisted of minor bleeding in four subjects. Symptomatic reocclusion occurred in one. Debulking of the thrombus mass by a high speed rotating impeller (n = 1) and stenting (n = 3) were used as additional interventions. An underlying anatomical abnormality was present in two patients. Long term follow up revealed normal patency in all patients and normal valve function in four patients. Symptomatic venous insufficiency with valve dysfunction was present in the two with a second thrombotic episode.Thus catheter-directed infusion of recombinant staphylokinase in patients with deep vein thrombosis appears feasible and may be associated with a high frequency of thrombolysis. Larger studies to define the clinical benefit of this treatment appear to be warranted.


2021 ◽  
pp. 1358863X2110429
Author(s):  
Samuel Z Goldhaber ◽  
Elizabeth A Magnuson ◽  
Khaja M Chinnakondepalli ◽  
David J Cohen ◽  
Suresh Vedantham

Catheter-directed thrombolysis (CDT) has been utilized as an adjunct to anticoagulant therapy in selected patients with deep vein thrombosis (DVT) for approximately 30 years. CDT used to be limited to patients with DVT causing acute limb threat and those exhibiting failure of initial anticoagulation, but has expanded over time. Randomized trials evaluating the first-line use of CDT for proximal DVT have demonstrated that CDT does not produce a major reduction in the occurrence of post-thrombotic syndrome (PTS) and that it is poorly suited for elderly patients and those with limited thrombus extent or major risk factors for bleeding. However, CDT does offer selected patients with acute iliofemoral DVT improvement in reducing early DVT symptoms, in achieving reduction in PTS severity, and in producing an improvement in health-related quality of life (QOL). Clinical practice guidelines from medical and surgical societies are now largely aligned with the randomized trial results. This review offers the reader an update on the results of recently completed clinical trials, and additional guidance on appropriate selection of patients with DVT for catheter-directed thrombolytic therapy.


2016 ◽  
Vol 32 (1) ◽  
pp. 61-65 ◽  
Author(s):  
J Davies ◽  
R Tippet ◽  
A Watson ◽  
J Metcalfe

Catheter-directed thrombolysis is becoming increasingly considered in the treatment of acute ileofemoral deep vein thrombosis. By targeting occlusive thrombi early, it is possible to mitigate the symptoms of post-thrombotic syndrome, which include oedema, pain, and ulceration. NICE guidelines recommend the use of catheter-directed thrombolysis in those without contraindications to treatment. The main risk of thrombolysis is bleeding; however, other side effects such as allergy have been reported. We present a 50-year-old man who presented with an acute left-sided ileofemoral deep vein thrombosis. He underwent catheter-directed thrombolysis in our centre to good effect, and ultimately he required stenting due to the presence of a May–Thurner lesion. His first day of thrombolysis, however, was complicated by a massive systemic inflammatory response syndrome response resulting in pyrexia and tachycardia, rigors, and myalgia. His deterioration in observations corresponded with a huge rise in D-dimer levels from an admission baseline of 1465 ng/ml to 182,835 ng/ml. We hypothesize that rapid breakdown of thrombus in this patient resulted in a lysis-type syndrome, presenting with a systemic inflammatory response syndrome response. Several questions are raised here including why the patient responded in this way, and whether there could be a way to predict response ahead of time? Fortunately, our patient came to no harm and continues to do well, with no evidence of further thrombosis on surveillance ultrasound. This case highlights an important complication of thrombolysis and reminds us that complications are not just limited to bleeding. Despite the short-term effects in this young fit patient, concerns must be raised about potential safety in the frailer and more elderly patient demographic in which such a large inflammatory response could be more detrimental.


2014 ◽  
Vol 29 (1_suppl) ◽  
pp. 135-139 ◽  
Author(s):  
J Grommes ◽  
KT von Trotha ◽  
MA de Wolf ◽  
H Jalaie ◽  
CHA Wittens

The post-thrombotic syndrome (PTS) as a long-term consequence of deep vein thrombosis (DVT) is caused by a venous obstruction and/or chronic insufficiency of the deep venous system. New endovascular therapies enable early recanalization of the deep veins aiming reduced incidence and severity of PTS. Extended CDT is associated with an increased risk of bleeding and stenting of residual venous obstruction is indispensable to avoid early rethrombosis. Therefore, this article focuses on measurements during or after thrombolysis indicating post procedural outcome.


Sign in / Sign up

Export Citation Format

Share Document